STRATEC Biomedical AG / Key word(s): Preliminary Results/Change in Forecast
18.10.2012 21:38

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

STRATEC reports preliminary figures and adjusts financial guidance
- Sales of EUR 87.6 million in 9M/2012 (+ 9.3%; 9M/2011: EUR 80.2 million) - EBIT margin of 15.3% in 9M/2012 (9M/2011: 18.8%) - Consolidated net income of EUR 10.9 million in 9M/2012   (+10.4%; 9M/2011: EUR 9.8 million)
- Earnings per share of EUR 0,93 in 9M/2012 (+9,4%; 9M/2011: EUR 0.85) - 2012 guidance reduced: Sales of EUR 120 million to EUR 125 million   / EBIT margin: 14% - 16%

Birkenfeld, October 18, 2012

STRATEC Biomedical AG, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard, TecDAX) today announces its preliminary figures for the period from January 1 to September 30, 2012.

At EUR 87.6 million, nine-month sales were 9.3% ahead of the previous year's figure of EUR 80.2 million. The EBIT margin for the period amounted to 15.3%. Adjusted for a one-off item of EUR 3.3 million posted in the first quarter of 2012 in connection with the write-down of a development project, sales amounted to EUR 84.3 million with a corresponding adjusted EBIT margin of 15.9%.

At EUR 10.9 million, consolidated net income was 10.4% higher than the equivalent figure of EUR 9.8 million for the first nine months of 2011. If the previous year's figure is adjusted for a one-off tax back payment of EUR 1.6 million incurred in 2011, then consolidated net income in 2012 was 5.0% lower than the same period in the previous year (EUR 11.4 million).
STRATEC expects to report sales of between EUR 120 million and EUR 125 million (previous guidance: EUR 125 million to EUR 139 million) for the 2012 financial year ending December 31, 2012. The EBIT margin for the full-year is expected to amount to between 14% and 16% (previous guidance: 17% to 19%).

This lower than expected sales and earnings performance is attributable to weak revenues from maintenance and spare parts and related benefits of scaling effects, market launches being implemented later than expected at our customers, and to a temporarily weaker gross margin for new analyzer systems.

Further details about the business performance in the first nine months of 2012 will be published in the interim report on October 24, 2012.

---

Information and Explaination of the Issuer to this News:
About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.

Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
ir@stratec.com
www.stratec.com

18.10.2012 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

 
Language:     English
Company:      STRATEC Biomedical AG
              Gewerbestr. 37
              75217 Birkenfeld
              Germany
Phone:        +49 (0)7082 7916 0
Fax:          +49 (0)7082 7916 999
E-mail:       info@stratec.com
Internet:     www.stratec.com
ISIN:         DE0007289001
WKN:          728900
Indices:      TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart  
End of Announcement DGAP News-Service  

---